# Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC

> **NCT07703228** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 38 (estimated)

## Conditions studied

- NSCLC (Advanced Non-small Cell Lung Cancer)
- NSCLC Stage IIIB~IV
- Second-line Therapy
- Metastases

## Interventions

- **DRUG:** Sacituzumab tirumotecan
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT07703228
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-08-13
- **Primary completion:** 2027-09-30
- **Final completion:** 2028-03-13
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-07-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07703228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07703228, "Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07703228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*